MD PhD. Oncologist at Oslo University Hospital. Medical oncology and cancer research. Mostly melanoma and immunotherapy. Private account. 🇳🇴🇸🇪🇬🇧
Joined April 2009
- Tweets1.3K
- Following1.3K
- Followers276
- Likes1.9K
Henrїk Jespersen retweeted
New #JITC article: "Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial)" jitc.bmj.com/content/14/3/e0…
@OlofssonBagge @SahlgrenskaAcad
Having a hard time believing this. Can’t wait to see this scrutinized, and replicated. – at Oslo, Norway
Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive!
Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival. However, there was always the question of systematic bias selecting for healthier patients in morning infusions, when frailer patients may not be able to come to receive morning infusions. This could potentially explain retrospective results, that may seem too good to be true…
Now we have a randomized clinical trial coming from Dr Zhang and colleagues showing a hazard ratio for Overall Survival of … 0.45 ! Lung cancer, chemo-immunotherapy first-line
Looking forward to dig further into the data, and these findings for sure have to be replicated (we are working on that 🇨🇭 @SAKK_ch)
But impressive efforts and results, congrats to the authors.👏 @Alfdoc2
Henrїk Jespersen retweeted
Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive!
Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival. However, there was always the question of systematic bias selecting for healthier patients in morning infusions, when frailer patients may not be able to come to receive morning infusions. This could potentially explain retrospective results, that may seem too good to be true…
Now we have a randomized clinical trial coming from Dr Zhang and colleagues showing a hazard ratio for Overall Survival of … 0.45 ! Lung cancer, chemo-immunotherapy first-line
Looking forward to dig further into the data, and these findings for sure have to be replicated (we are working on that 🇨🇭 @SAKK_ch)
But impressive efforts and results, congrats to the authors.👏 @Alfdoc2
Henrїk Jespersen retweeted
I am grateful to Crown Prince Regent Haakon and Crown Princess Mette-Marit of Norway for the audience.
We discussed strengthening cultural ties between our countries and further support for the Grain from Ukraine humanitarian initiative.
All of us in Ukraine deeply appreciate Norway’s defense and humanitarian support, as well as its efforts in developing a European plan for achieving a just peace and reliable security guarantees.
🇺🇦🇳🇴
Henrїk Jespersen retweeted
Very proud to present the latest review we wrote about extracellular vesicles in uveal melanoma published in Cancer Letters! @Ornella_Urzi @OlofssonBagge #EV #UM sciencedirect.com/science/ar…
Henrїk Jespersen retweeted
A modified classification of progressive disease based on PD patterns in patients treated with immune checkpoint inhibitors showed an association with postprogression survival (PPOS) across various solid tumor. ja.ma/4gGdagZ
Henrїk Jespersen retweeted
What is the best 1st line immunotherapy regimen for pts with adv/meta melanoma?
To me, this remains an unsolved Q because IPI-NIVO and RELA-NIVO are more toxic than NIVO, and post-progression access to IPI-containing regiment in both trials was limited ➡️ mini 🧵1/2
1⃣ RELATIVITY-047 presented 3-y OS results
Here is some context for post-progression therapy👇
Henrїk Jespersen retweeted
November @sitcancer #JITC Reading List by Social Media Editor @Praveen_IO selection #4: 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by @UTSWMedCenter @umiamimedicine bit.ly/3CGwont
Henrїk Jespersen retweeted
📢New @myESMO guidelines in press - Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
@ProfGLongMIA @beckilee @TeresaSAmaral
@OmidHamidMD @angelesclinic @matguc
@DoniaMarco
doi.org/10.1016/j.annonc.202…
Henrїk Jespersen retweeted
An important piece of work by @SocSurgOnc for clinicians managing #melanoma patients.
Bottom line: gene-expression profiling (GEP) shows much promise but not quite ready for melanoma primetime.
Honoured to be involved with this prestigious committee 🇺🇲🇬🇧
SSO announces publication of its 1st consensus statement, Assessing the Evidence For and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma. Developed by melanoma specialists around four clinical questions on GEP testing for primary CM. ow.ly/OSAa50TWrhM
Henrїk Jespersen retweeted
BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Physics to John J. Hopfield and Geoffrey E. Hinton “for foundational discoveries and inventions that enable machine learning with artificial neural networks.”
Henrїk Jespersen retweeted
Happy to share the final version of our @eLife manuscript on tumor-reactive lymphocytes (TRLs) in uveal melanoma
elifesciences.org/articles/9…
By using single cell seq and a live biobank of TILs & patient-derived mice (xenografts) we tease out the molecular characteristics of TRLs!
->
Henrїk Jespersen retweeted
@HildurHelg presents out Swedish data showing no OS benefit with adjuvant immunotherapy for stage III melanoma. #ESMO24
Can we all just agree now that these patients are cured? Time to stop the cautious talk about “long term benefit” and start giving patients with stage IV melanoma real hope.
Final survival analysis of CM067 (nivo/ipi+nivo/ipi) in advanced melanoma.
nejm.org/doi/full/10.1056/NE… – at Oslo, Norway
Henrїk Jespersen retweeted
New research from @PennCancer, published in @Cancer_Cell, challenges fundamental assumptions about how combination #PD1 #CTLA4 #immunotherapy activates different types of #Tcells to defeat cancer. spr.ly/6012m9hL2
Begriper ikke at norske myndigheter og folk ikke skjønner dette. Kanskje er den hjemmesmurte matpakka et stolt symbol for måtehold og selvstendighet, men den er også en forsterker av sosial urettferdighet og burde skrotes. @Kunnskapsdep – at Oslo, Norway
Why free school meals are the hidden bedrock of a better society sciencefocus.com/comment/fre… via @GilesYeo @ajjolley
Henrїk Jespersen retweeted
Determinants of resistance and response to melanoma therapy @NatureCancer nature.com/articles/s43018-0…
Henrїk Jespersen retweeted
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials out on @JCO_ASCO
Study investigates the impact of immunosuppressive treatment💊 on survival in patients with various tumor types receiving anti–PD-1 + anti–CTLA-4 therapy🧪, utilizing data from six international phase II/III trials. The analysis included 834 out of 1,959 patients who were treated with corticosteroids for treatment-related adverse events (trAEs), with 10% also receiving second-line immunosuppressants.
✅Results showed that higher peak corticosteroid doses were significantly associated with worse PFS and OS, whereas cumulative corticosteroid dose was not linked to survival outcomes. Due to the limited number of patients receiving second-line immunosuppression, no definitive conclusions could be drawn regarding its impact on survival.
These findings suggest a need to reconsider current irAE management strategies, advocating for the use of lower corticosteroid doses when possible.
#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth @anmwongNZ @lungoncdoc @ADesaiMD @bavilima @realbowtiedoc
